Response-guided therapy: Optimizing treatment now and in the future

Antiviral Therapy

Volumn 13, Issue SUPPL. 1, 2008, Pages 1-2

  Marcellin, Patrick ^a   Rizzetto, Mario ^b  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIBIOTIC THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPONSE GUIDED THERAPY; TREATMENT PLANNING; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 42149184703     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (9)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43:250-257.
4. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875-881.
5. Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008; 13 Suppl 1:3-8.
6. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13 Suppl 1:9-16.
7. Berg T, Carosi G. Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther 2008; 13 Suppl 1:17-22.
8. Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antivir Ther 2008; 13 Suppl 1:23-30.
9. Jensen DM, Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther 2008; 13 Suppl 1:31-36.